Senior User Experience Researcher, LunaPBC
Biography
Focusing on developing participant-focused research methods, surfacing priorities, needs, hierarchies, and categories through the mental models of people directly affected by clinical and diagnostic research. Ian has a long history in Human-centered research and advocacy, diagnosed with a rare disease at 5 years old he has worked his whole career to bring together the shared experience of participants and the proven methods of product development.
Talk
Computational Social Choice Theory's Impact on the Collection and Understanding of Real-World Data
The fields of Computational Social Choice, UX Research, and product development have vastly outpaced the medical field in their ability to collect, categorize, and understand real-world data points to improve the lives of their "users." By implementing these lessons into the clinical landscape we can leap-frog years of systems growth and evolution without having to re-invent the wheel. For RWE to be effective, it must be representative of people's real lives, in their living rooms and around their dining tables, growing at the same pace as real life. How exactly can this be done? Case studies and an explanation of novel methodologies will pave the way.
Session Abstract – PMWC 2022 Silicon Valley
Track Chair:
Keith Yamamoto, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support
Sessions:
- Realizing the Promise of Precision Medicine Using Real-world Evidence (PANEL)
Session Chair: Atul Butte, UCSF
- Nancy A. Dreyer, IQVIA
- Mark Laabs, RCRF
- Rhonda Cooper-DeHoff, University of Florida
- Chris Boone, Abbvie - Opportunities and Challenges in Using Real World Data (RWD) (PANEL)
Session Chair: Vivek Rudrapatna, UCSF
- Mark Hoffman, Childrens Mercy Hospital
- Ida Sim, UCSF
- Julian Hong, UCSF - How Are Patient Data Revolutionizing Precision Medicine? (PANEL)
Session Chair: Clara Lajonchere, UCLA
- Sharon Terry, Genetic Alliance
- Farid Vij, Invitae
- Latha Palaniappan, Stanford - Government Partnerships: California Initiative to Advance Precision Medicine
Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
- William Kim, UCSD
- Mike Snyder, Stanford - Leveraging RWE to Create Value (PANEL)
Session Chair: Latha Palaniappan, Stanford
- Brook Schroeder, Illumina
- Suzanne Belinson, Tempus
- Stacey Dacosta Byfield, Optum Genomics - Computational Social Choice Theory's Impact on the Collection and Understanding of RWD
- Ian Terry, LunaDNA - PMWC Showcase
- Chris Williams, MMRF
- Jason Crites, Assurance Health Data
